Exelixis | EXEL - Ebitda





Ebitda Cambiamento Data
Acadia Pharmaceuticals USD 20.31M 15.44M 2025-12
Agios Pharmaceuticals USD -120.31M 4.82M 2025-12
Akebia Therapeutics USD 14.03M 17.19M 2025-03
Amgen USD 5.14B 775M 2025-12
AstraZeneca USD 5.67B 1.29B 2026-03
Bayer EUR 4.45B 2.49B 2026-03
BioMarin Pharmaceutical USD 146.05M 170.22M 2026-03
Bristol-Myers Squibb USD 2.88B 1.36B 2025-12
Cytokinetics USD -169.32M 19.48M 2026-03
Eisai JPY -335M 30.43B 2026-03
Eli Lilly USD 12.14B 4.26B 2025-12
Esperion Therapeutics USD -9.93M 24.99M 2025-09
Exelixis USD 258.29M 15.43M 2026-03
Genmab DKK 186M 291M 2025-12
Glaxosmithkline GBP 2.77B 1.98B 2026-03
Incyte USD 367.97M 46.53M 2026-03
Ionis Pharmaceuticals USD -200.02M 42.89M 2025-12
MacroGenics USD -30.2M 52.15M 2026-03
Merck USD 6.3B 2.09B 2025-12
Moderna USD -790M 582M 2025-12
Nektar Therapeutics USD -31.81M 70K 2023-09
Neurocrine Biosciences USD 193.3M 25.1M 2026-03
Novartis USD 5.3B 530M 2026-03
Pfizer USD 5.99B 5.23B 2026-03
Puma Biotechnology USD 729K 11.36M 2024-06
Sanofi EUR 2.72B 2.94B 2026-03
Takeda JPY 150.25B 297.88B 2026-03
Ultragenyx Pharmaceutical USD -99.43M 57.35M 2025-12
Xencor USD -51.05M 55.28M 2025-12